Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - Management in adults

Endokrynologia Polska

Volumn 61, Issue 1, 2010, Pages 142-155

  Ambroziak, Urszula ^a   Bednarczuk, Tomasz ^a   Ginalska Malinowska, Maria ^b   Malunowicz, Ewa Maria ^b   Grzechocińska, Barbara ^a   Kamiński, Paweł ^a   Bablok, Leszek ^a   Przedlacki, Jerzy ^a   Bar Andziak, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

21 hydroxylase; Congenital adrenal hyperplasia; Glucocorticosteroids

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE; PREDNISONE;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL CORTEX TUMOR; ADRENAL INSUFFICIENCY; ADRENALECTOMY; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; ENDOMETRIUM; GENE THERAPY; HUMAN; HYPERANDROGENISM; HYPERCORTISOLISM; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LEYDIG CELL TUMOR; METABOLIC SYNDROME X; PLASTIC SURGERY; QUALITY OF LIFE; REVIEW;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; FEMALE; GLUCOCORTICOIDS; HUMANS; METABOLIC SYNDROME X; QUALITY OF LIFE; STEROID 21-HYDROXYLASE;

EID: 77950524261     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Rev 2000;21: 245-291. (Pubitemid 32275589)
2. Romer ET. Wrodzony przerost kory nadnerczy. In: Syrenicz A (ed.). Endokrynologia w codziennej praktyce lekarskiej. Wydawnictwo Pomorskiej Akademii Medycznej w Szczecinie 2009: 519-556.
3. Program badańprzesiewowych noworodków w Polsce, www.mz.gov.pl
4. Pang S, Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993;2: 105-139. (Pubitemid 23248989)
5. Speiser PW, Dupont I, Zhu D et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90: 584-595.
6. New MI. Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91: 4205-11214
7. Ambroziak U. Przełom nadnerczowy. In: Hryniewiecki T (ed.). Stany nagłe. Medical Tribune Polska, Warszawa 2009: 198-200.
8. Merke DP, Chrousos GP, Esenhofer G et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Eng J Med 2000;343: 1362-1368.
9. Weise M, Mehlinger SL, Drinkard B et al. Patients with classic congenital hyperplasia have decreased epinephrine reserve undergoing short term high intensity exercise. J Clin Endocrinol Metab 2004;89: 3679-3684.
10. Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008;93: 653-660. (Pubitemid 351398534)
11. Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30: 2017-2229
12. Barnes RB, Rosenfield RL, Ehrmann DA et al. Ovarian hyperandrogenism as a result of congenital adrenal virilising disorders: evidence for perinatal masculinization of neuroendocrine function in woman. J Clin Endocrinol Metab 1994;79: 1328-1333.
13. Ogilvie CM, Croucht NS, Rumsby G et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol 2006;64: 2-11.
14. Russo G, Paesano P, Taccagni G et al. Ovarian adrenal-like tissue in congenital adrenal hyperplasia. N Eng J Med 1998;339: 853-854. (Pubitemid 28447470)
15. Wilkins L, Cara J. Further studies on the treatment of congenital adrenal hyperplasia with cortisone: Effects of cortisone treatment on testicular development. J Clin Endocrinol Metab 1954;14: 287-296.
16. Reisch N, Flade L Scherr M et al. High prevalence of reduced fecundity in man with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009;94: 1665-1670.
17. Avila NA, Premkumar A, Merke DP. Testicular adrenal rests tissue in congenital adrenal hyperplasia: comparison of MR imaging and sonographic findings. Am J Roentgenol 1999;172: 1003-1006. (Pubitemid 29505628)
18. Anderson JR, McLean Ross AH. Ectopic adrenal tissue in adults. Postgrad Med 1980;56: 806-808.
19. Stikkelbroeck NM, Otten BJ, Pasic A et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86: 5721-5728. (Pubitemid 33152615)
20. Claahsen-van derGrinten HL, Sweep FC, Blickman JG et al. Prevalence of testicular adrenal rest tumors in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007;157: 339-344. (Pubitemid 47603539)
21. Rutgers JL, Young RH, Scully RE. The testicular tumor of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988;12: 503-513.
22. Jain SH, Sadow PM, Nose V et al. A patient with ectopic Cortisol production derived from malignant testicular masses. Nat Clin Practice Endocrinology &Metabolism 2008;4: 695-699.
23. Walker BR, Skoog SJ, Winslow BH et al. Testis sparing surgery for steroid unresponsive testicular tumours of the adrenogenital syndrome. J Urol 1997;157: 1460-1463.
24. Claahsen-van der Grinten HL, Otten BJ, Takahashi S et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary - gonadal function before and after successful testis-sparing surgery in eight patients. J Clin Endocrinol Metab 2007;92: 612-615. (Pubitemid 46255304)
25. Azziz R, Zacur A. 21-hydroxylase deficiency in female hyperandrogenism;screening and diagnosis. J Clin Endocrinol Metab 1989;69: 577-584. (Pubitemid 19221230)
26. Baron JJ, Baron J. Differential diagnosis of hirsutism in girls between 15-19 years old. Ginekol Pol 1993;64: 267-269.
27. Moran C, Azziz R, Carmina E et al. 21-hydroxlase deficient nonclassical adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Ostet Gynecol 2000;183: 1468-1474. (Pubitemid 32061209)
28. Jaresch S, Kornety E, Kley HK et al. Adrenal incidentaloma and patients with homozygous and heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992;74: 685-689.
29. Bauman A, Bauman CG. Virilizng adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia. JAMA 1982;248: 3140-3141.
30. Dubey GK, Dotiwalla HH, Choubey BS et al. A case report of virilising adrenal cortical carcinoma. J Assoc Physicians India 1981;29: 491-493.
31. Eugster EA, Dimeglio LA, Wright JC et al. Hight outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a metaanalysis. J Pediatr 2001;138: 26-32. (Pubitemid 32097137)
32. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997;82: 3926-3929. (Pubitemid 27525488)
33. Mora S, Saggion F, Russo G. Bone density in young patients with congenital adrenal hyperplasia. Bone 1996;18: 337-340. (Pubitemid 26149345)
34. Jaaskeleinen J, Voutilainen R. Bone mineral density in relation to glucocorticoid substitution therapy in adults patients with 21-hydroxylasede- ficiency. Clin Endocrinol 1996;45: 707-713. (Pubitemid 27032316)
35. King JA, Wiśniewski AB, Bańkowski BJ et al. Long term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006;91: 865-869.
36. Falhammer H, Filipsson H, Holmdahl G et al. Fractures and bone mineral density in adult woman with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92: 4643-4649. (Pubitemid 350223439)
37. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ et al. Normal bone mineral density and lean body mass, but increased fat mass in young adult patients with congenital adrenal hyperplasia. J Cin Endocrinol Metab 2003;88: 1036-1042.
38. Ambroziak U, Bednarczuk T, Przedlacki J et al. Bone metabolism and elements of metabolic syndrome in young adults with CAH in chronic glucocorticoid treatment. ENDO 2009, Washington.
39. Charmandari E, Johnston A, Brook CG et al. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 2001;169: 65-70. (Pubitemid 32273215)
40. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000;43: 533-549. (Pubitemid 30322070)
41. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Rev 2001;22: 36-52. (Pubitemid 32187802)
42. Sartorato P, Zulian E, Benedini S et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients withclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92: 1015-1018. (Pubitemid 46465677)
43. Arlt W, Willis DS, Doherty EJ et al. Current management and morbidity of adult patients with congenital adrenal hyperplasia - analysis of the United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE). ENDO 2009, Washington.
44. Kula K, Słowikowska R. Sexual differentiation of me human brain. Przegl Lek 2000;57: 41-44.
45. Charmandari E, Brook CCD, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol 2004;151: 77-82. (Pubitemid 39627059)
46. Malouf MA, Migeon CJ, Carson KA et al. Cognitive outcome in adult woman affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2006;65: 142-150.
47. Nass R, Baker S. Learning disabilities in children with congenital adrenal hyperplasia. J Child Neurol 1991;6: 306-312.
48. Witchel SF, Nayak S, Suda-Hartman M et al. Newborn screening for 21-hydroxylase deficiency : Results of CYP21 molecular genetic analysis. J Pediatr 1997;131: 328-331. (Pubitemid 27495262)
49. LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87: 4048-4053.
50. Malunowicz EM. The diagnosis of CAH due to 21-hydroxyIasedeficiency-from false results to discovery of a new type of steroidogenesis defect (APHD). Endokrynol Ped 2003;2: 63-68.
51. New MI, Lorenzen F, Lemer AJ et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endcrinol Metab 1983;57: 320-326. (Pubitemid 13032483)
52. Malunowicz EM, Mitkowska Z, Bal K et al. Definitive diagnosis of enzymatic deficiences of steroidogenesis in at-risk newborns and infants by urinary marker analysis using GC/MS-SIM. Horm Res 1997;48: 243-251. (Pubitemid 27490223)
53. Nimkam S, Lin-Su K, Berglind N, Wilson RC et al. Aldosterone-to- reninratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007;92: 137-142. (Pubitemid 46067521)
54. Azziz R, Hincapie LA, Knochenhauer ES et al. Screening for 21-hydroxylase - deficient non-classic adrenal hyperplasia among hyperandrogenic woman: a prospective study. Fertile Steril 1999;72: 915-925. (Pubitemid 29505460)
55. Escobar-Morreale HF, Sanchon R, San Milan J L. A prospective study of the prevalence of non-classical congenital adrenal hyperplasia among woman presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93: 527-533. (Pubitemid 351240826)
56. Malunowicz EM. Nieklasyczna postaćwrodzonego przerostu kory nadnerczy z powodu niedoboru 21-hydroksylazy (nk-wpn) u dziewczynek i kobiet z objawami androgenizacji. Endokrynologia Ped 2008;7: 9-18.
57. Miller WL. The adrenal cortex. In: Rudolph AM, Hoffman JIE (ed.). Pediatrics. Appleton &Lange, Norwalk 1991: 1584-1614.
58. Brunton LL. Goodman &Gilman's the pharmacological basis of therapeutics. McGraw Hill 2006.
59. Van Vyk JJ, Ritzen EM. The role of bilateral adrenalectomy in thetreatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003;88: 2993-2998. (Pubitemid 36877460)
60. Premawardhana LG, Hughes IA, Read GF et al. Longer term outcomein females with congenital adrenal hyperplasia (CAH): the Cardiffexperience. Clin Endocrinol 1997;46: 327-332.
61. Spritzer P, Billaud L, Thalabard JC et al. Cyproteron acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J Clin Endocrinol Metab 1990;70: 642-646. (Pubitemid 20092437)
62. Falsetti L, Gabera A, Legrenzi L et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141: 361-367. (Pubitemid 29529489)
63. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemia hiperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12: 243-252. (Pubitemid 43913770)
64. Merke DP, Culter GB Jr. New ideas for medical treatment of congenitaladrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30;121-135. (Pubitemid 32381717)
65. New MI, Carlson A, Obeid J et al. Prenatal diagnosis for congenitaladrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001;86: 5651-5657.
66. Ginalska-Malinowska M, Romer T. Leczenie prenatalne wrodzonego przerostu nadnerczy - za I przeciw. Gin Prakt 2002;3: 91-93.
67. Ginalska-Malinowska M, Romer T, Jezuicka J et al. Wrodzony przerost nadnerczy: diagnostyka i leczenie prenatalne. Gin Pol 1997;68: 310-316.
68. Malunowicz EM, Ginalska-Malinowska M, Romer TE et al. The influence of prenatal dexamethasone treatment on urinary excretion of adrenocortical steroids in newborns. Eur J Pediatr 1998;157: 539-543. (Pubitemid 28311477)
69. Romer TE, Ginalska-Malinowska M. Successful prenatal treatment of congenital adrenal hyperplasia resulting from the 21-hydroxylasedeficiency: is prenatal diagnosis in a mother at risk essential? Endokrynol Pol 1987;38: 125-130. (Pubitemid 18009927)
70. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005;365: 2125-2136.
71. Struthers AD, Mac Donalds TM. Review of aldosterone and angiotensin II induced target organ damage and prevention. Cardiovasc Res 2004;61: 663-670.
72. Schaison G, Couzinet B, Gourmelen M et al. Angiotensin and adrenal steroidogenesis: study of 21-hydroxylase deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980;51: 1390-1394. (Pubitemid 11199633)
73. Charmandari E, Chousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia. Do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann. N.Y. Acad Sci 2006;1083: 37-53. (Pubitemid 44955466)